Charles River Laboratories International, Inc. - CRL STOCK NEWS

Charles River Laboratories International (NYSE: CRL) announces the launch of Apollo™, a secure cloud-based platform designed for drug developers. This platform streamlines access to study data, milestones, documents, and cost estimates, ultimately enhancing decision-making and client experience. Apollo is part of Charles River's digital strategy, fostering real-time data access and self-service tools for clients. Currently live for ongoing studies, Apollo aims to improve efficiency in preclinical studies.

Charles River Laboratories (NYSE: CRL) has launched its off-the-shelf pHelper offering designed to streamline adeno-associated virus (AAV)-based gene therapy programs from discovery to commercial manufacturing. Available in Research Grade, High Quality, and Good Manufacturing Practice grades, this product aims to secure supply chains and support regulatory filings with reliable manufacturing. Key benefits include immediate supply, consistent quality, and cost reduction. The launch will be highlighted at the Gene Therapy Spotlight event on March 13 in London, showcasing the role of plasmid DNA in gene therapy manufacturing.

Charles River Laboratories (CRL) reported a strong performance for Q4 2022, with revenues of $1.10 billion, up 21.5% year-over-year, and full-year revenues reaching $3.98 billion, reflecting a 12.3% increase. GAAP EPS for Q4 was $3.65, a 36.7% rise, attributed to gains from the Avian Vaccine sale. Non-GAAP EPS also rose to $2.98, an increase of 19.7%. Looking ahead, CRL anticipates revenue growth of 1.5% to 4.5% in 2023, hindered by non-human primate (NHP) supply chain issues. Despite challenges, management emphasized sustainability in long-term growth.

Charles River Laboratories (CRL) has signed a multi-program agreement with Pioneering Medicines, enabling access to its AI-driven drug solution, Logica. Designed to expedite drug discovery, Logica combines Valo Health’s Opal Computational Platform and Charles River’s preclinical expertise. The collaboration aims to generate optimized small molecules for unmet medical needs within a 2-year timeframe. This integrated platform is expected to enhance efficiency in drug development, reducing costs tied to success. Flagship Pioneering's initiative, Pioneering Medicines, seeks to leverage innovative platforms to develop transformative treatments.

Charles River Laboratories (NYSE: CRL) has partnered with Purespring Therapeutics to develop a gene therapy platform focused on kidney diseases, affecting about 840 million people globally. This collaboration utilizes Charles River's eXpDNA™ plasmid manufacturing capabilities, bolstering their CDMO services in cell and gene therapy. Purespring aims to innovate treatments targeting podocytes, leveraging a lower-dose, local delivery approach to enhance efficacy and safety. Supported by significant investments, this initiative seeks to accelerate the development of novel therapies, transforming kidney disease treatment and significantly improving patient outcomes.

Charles River Laboratories (NYSE: CRL) has launched its first HCP-ELISA Kit for detecting residual host cell proteins in CHO-based biotherapeutics. This kit boasts an industry-leading sensitivity of 0.1 ng/mL and 90% antibody coverage, utilizing unique chicken IgY antibodies. This method enhances specificity compared to conventional IgG antibodies, which improves impurity control in drug development. The kit supports clients either for self-use or via Charles River’s expert services. This launch is a significant addition to their Biologics Testing portfolio and indicates a continued commitment to pioneering solutions in the biopharmaceutical field.

Charles River Laboratories International, Inc. (NYSE: CRL) will announce its Q4 2022 and full-year 2022 financial results along with guidance for 2023 on February 22, before market opening. A conference call is scheduled for 8:30 a.m. ET on the same day to discuss the results. Investors can access the live webcast through the Investor Relations section of the company's website. Charles River provides critical services and products to pharmaceutical, biotechnology companies, and academic institutions worldwide, aiming to enhance the research and development of new therapies.

Charles River Laboratories (NYSE: CRL) announced the acquisition of SAMDI Tech, Inc. for $50 million, enhancing its drug discovery capabilities through SAMDI's proprietary mass spectrometry technology. This strategic move, marking the culmination of a partnership that began in 2018, aims to improve high-throughput screening (HTS) solutions, accelerating drug discovery timelines and reducing associated costs. The technology offers significant advantages, including minimizing false positives and improving assay conditions. SAMDI Tech will become part of Charles River's Discovery and Safety Assessment segment, expected to augment their comprehensive library of drug discovery solutions.

Charles River Laboratories (NYSE: CRL) has partnered with Rznomics Inc. to utilize its expertise in adenoviral vector production, facilitating the clinical trials of RZ-001, an RNA-based gene therapy targeting hepatocellular carcinoma (HCC). RZ-001, the first ribozyme-based therapy approved by the FDA, aims to treat liver cancer, which accounts for 80% of primary liver cancer cases worldwide. Following its FDA IND approval in October, Rznomics is set to initiate a Phase I/IIa clinical study internationally and in Korea. This collaboration enhances Charles River's established capabilities in gene therapy and manufacturing services, promoting effective clinical development.